Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
about
The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyNKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple MyelomaAn integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers.Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapySoluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment.SheddomeDB: the ectodomain shedding database for membrane-bound shed markers.Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion.Quantification of anti-sperm antibody and soluble MICA/MICB levels in the serum of infertile people of the Li ethnic group in ChinaPotential for enhanced therapeutic activity of biological cancer therapies with doxycycline combinationCombination immune therapies to enhance anti-tumor responses by NK cells.Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.A killer choice for cancer immunotherapy.The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset.Cell carriers for oncolytic viruses: current challenges and future directions.Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies.Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia.NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitorsNatural Killer Cell (NK-92MI)-Based Therapy for Pulmonary Metastasis of Anaplastic Thyroid Cancer in a Nude Mouse Model.New prospects on the NKG2D/NKG2DL system for oncology.Serum soluble major histocompatibility complex class I-related chain A/B expression in patients with alcoholic liver disease in Hainan Li community.All-trans retinoic acid enhances cytotoxicity of CIK cells against human lung adenocarcinoma by upregulating MICA and IL-2 secretion.Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia.The Combined Antitumor Effects of 125I Radioactive Particle Implantation and Cytokine-Induced Killer Cell Therapy on Xenograft Hepatocellular Carcinoma in a Mouse Model.Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma.
P2860
Q28076473-1DAE0FC4-00E0-41FB-BDB3-9C8B7DCF2D96Q28080823-844F55B7-7A03-4D7F-8A9D-F5A99F326252Q34064494-8DFDBEE1-E6BA-4E62-A119-E060A1302381Q34918975-0B8CCFD5-371A-41E0-90CC-533BC0C9DB01Q35053561-89AA4831-16D8-4CDE-9BF1-D0429731C97FQ36329547-B4A15902-5CE2-4858-AE82-50B1E24DF2F1Q36351988-0A424980-77BC-47A9-9E00-115D1F4A7AACQ36412214-5D557378-3686-4A31-9422-2124E3894E40Q36750814-68A75127-7E55-4681-949D-A781924EDD6AQ37408550-6BB6A765-28D3-44C7-91EC-A380B055BA3BQ38107250-215559E4-6537-456C-B2BE-029DE95D5585Q38208944-30C8CBDD-8971-4D6F-A48D-F5BF8F064CE0Q38773798-AFA7DE59-548A-49A9-B9D5-B22DF10E642EQ38924531-7B402425-5F7C-480C-BEFE-2E52B9479EC5Q38940720-8A3C720B-7D2C-4A9D-9043-E5181DEBAE87Q39037081-15ED32B3-66FD-4498-91F6-D428511A7C04Q39049730-60E69170-78DD-45FB-BC25-85675A691CF4Q39798606-8DAA27A0-5D49-420F-8E03-082A015073F3Q41074467-F26E311D-D0E5-4451-8490-D949953E9C2CQ42796257-1BAC2766-2DCD-44DF-8F9C-459BB54E19ABQ43209848-1267A22E-065A-4552-9E99-1516209030A4Q47111085-5FA17EF0-70AA-451F-9939-5D46828D8197Q48312107-8C9B212C-665A-4887-9F7C-F2F1EDF8243CQ49543140-C470B76C-07E7-41ED-BA04-53E5D74DA726Q51633659-65E3B9CF-AC7B-42DD-A4B3-F55A17E0C4B8
P2860
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
@ast
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
@en
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
@nl
type
label
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
@ast
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
@en
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
@nl
prefLabel
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
@ast
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
@en
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
@nl
P2093
P2860
P1476
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
@en
P2093
Baocheng Huang
Padma Sampath
Rachel Sikorski
Stephen H Thorne
P2860
P304
P356
10.1097/CJI.0B013E31820E1B0D
P577
2011-04-01T00:00:00Z